Genetics and Genomics Firm iLife Discoveries Brings Over 50 Genetic Tests to India

iLife Discoveries, the Genetics and genomics firm is looking at bringing benefits of genetic tests for providing appropriate diagnostics and treatment options for various diseases in India.

The core areas of the company include oncology, mother and child initiative and neuro-psychiatry. "We have set up a core laboratory facility in India to translate genetics and genomics information from labs to bed-sides in hospitals," said iLife Discoveries Founder and CMD Anand Gupta.

About Genetic Testing
Genetic testing helps to confirm a genetic condition in an individual and involves q complex laboratory techniques

The firm currently has a total of around 50 tests such as psychogenetic tests, new born screening tests and MammaPrint and Blueprint tests for breast cancer, among others, for early diagnostics and treatment.

"For neuro-psychiatry area, we have collaborated with a company called AB-Biotics for bringing a test called neuropharmagen in India for people suffering from depression which is a huge problem in the country," said Gupta.

Oncology is another area, which the company wants to focus on and for this, "Among others, we have also partnered with the US-based firm Agendia for their tests, MammaPrint and BluePrint."

Genetic Testing for Intellectual Disability
The cause of intellectual disability is often linked to the genes. Genetic testing helps to diagnose these defects in genes.

The company is also in the process of entering into more exclusive tie-ups with various other companies and is also looking for expanding its workforce for future growth, said Gupta.

Source-Medindia

Direction in Genetic Testing for Certain Types of Muscular Dystrophy Offered in New Guideline
Guidance on how doctors should evaluate symptoms, family history and ethnicity, conduct a physical exam and certain lab tests.

Genetic Testing can Identify Men at Risk of Prostate Cancer
After a major international study identified 23 new genetic variants associated with increased risk of the disease, scientists can now explain a third of the inherited risk of prostate cancer.